Study Enumerates Personal, System-Wide Effects of Depression in the United States
Researchers evaluated differences in the burden of health outcomes between those with and without depression.
Researchers evaluated differences in the burden of health outcomes between those with and without depression.
SHP465 mixed amphetamine salts reduced symptoms of attention-deficit/hyperactivity disorder in adults, independent of ADHD treatment history.
Treatment rates for patients with major depressive disorder with an elevated PHQ-9 score were characterized in this study.
In order to assess the efficacy and safety of JZP-258, a lower sodium alternative product to sodium oxybate, study authors designed a double-blind, placebo-controlled, randomized withdrawal, multicenter study with an open-label safety extension.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Researchers conducted a study to investigate the bidirectional nature of the relationship between obesity and depression.
Clinical trials were conducted to assess the effect brexanolone and zuranolone, neuroactive steroids that are positive allosteric modulators of the gamma-aminobutyric acid receptor, on depression in postpartum women.
Investigators conducted a comprehensive literature search to identify key characteristics that best differentiate between bipolar I disorder and major depressive disorder.
Analysis of the HARMONY trial was conducted to evaluate the prevention of relapse in patients with dementia-related psychosis who have been treated with pimavanserin.